Sign in

    Brett Fishman

    Vice President and Senior Equity Research Analyst at KeyBanc Capital Markets Inc.

    Brett Fishbin is a Vice President and Senior Equity Research Analyst at KeyBanc Capital Markets Inc., specializing in Medical Technology sector coverage. He provides research and analysis for leading medtech companies such as Alcon, The Cooper Companies, ICU Medical, Inspire Medical Systems, Integer Holdings, LeMaitre Vascular, ResMed, Solventum, Sotera Health, STERIS, and UFP Technologies, and is noted for delivering actionable insights for institutional investors. Fishbin joined KeyBanc in 2017, following investment roles with the University of Wisconsin’s Applied Securities Program and an internship at Heartland Advisors, and was promoted to senior analyst after six years, including five focused on MedTech. He holds a BBA in finance, an MS in Applied Securities Analysis from the University of Wisconsin-Madison, and maintains Series 7, 63, 86, and 87 securities licenses.

    Brett Fishman's questions to Solventum (SOLV) leadership

    Brett Fishman's questions to Solventum (SOLV) leadership • Q2 2025

    Question

    Brett Fishman inquired about the underlying patient volume trends in the Dental Solutions business and asked to identify key new products to watch in the second half of the year.

    Answer

    CEO Bryan Hanson stated that the dental market has been stable, neither accelerating nor decelerating, and that the company's growth plan is not dependent on market improvement. He highlighted that growth will be driven by recently launched products gaining traction, specifically naming ClinPro Clear, Filtek EZ Match, and the Clarity Precision Grip attachments.

    Ask Fintool Equity Research AI